184 related articles for article (PubMed ID: 19091781)
1. Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.
Penault-Llorca F; Abrial C; Raoelfils I; Chollet P; Cayre A; Mouret-Reynier MA; Thivat E; Mishellany F; Gimbergues P; Durando X
Oncologist; 2008 Dec; 13(12):1235-45. PubMed ID: 19091781
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
[TBL] [Abstract][Full Text] [Related]
3. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy.
Amat S; Penault-Llorca F; Cure H; Le Bouedëc G; Achard JL; Van Praagh I; Feillel V; Mouret-Reynier MA; Dauplat J; Chollet P
Int J Oncol; 2002 Apr; 20(4):791-6. PubMed ID: 11894126
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
[TBL] [Abstract][Full Text] [Related]
5. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
6. [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].
Petráková K; Nenutil R; Grell P; Fabian P; Zichová I; Svoboda M; Palácová M; Vyzula R
Klin Onkol; 2008; 21(5):303-8. PubMed ID: 19202962
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
Med Oncol; 2011 Dec; 28 Suppl 1():S31-8. PubMed ID: 20844986
[TBL] [Abstract][Full Text] [Related]
8. Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile.
Mottolese M; Orlandi G; Sperduti I; Merola R; Buglioni S; Di Benedetto A; Pinnarò P; Perracchio L; Venturo I; Cognetti F; Cianciulli A
Am J Surg Pathol; 2007 Feb; 31(2):247-54. PubMed ID: 17255770
[TBL] [Abstract][Full Text] [Related]
9. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.
Abrial SC; Penault-Llorca F; Delva R; Bougnoux P; Leduc B; Mouret-Reynier MA; Mery-Mignard D; Bleuse JP; Dauplat J; Curé H; Chollet P
Breast Cancer Res Treat; 2005 Dec; 94(3):255-63. PubMed ID: 16267618
[TBL] [Abstract][Full Text] [Related]
10. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.
Faneyte IF; Schrama JG; Peterse JL; Remijnse PL; Rodenhuis S; van de Vijver MJ
Br J Cancer; 2003 Feb; 88(3):406-12. PubMed ID: 12569384
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
[TBL] [Abstract][Full Text] [Related]
13. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of mitotic and apoptotic index and the DNA cytometry in head and neck cancer.
Smilek P; Dusek L; Veselý K; Rottenberg J; Kostrica R
Neoplasma; 2005; 52(3):199-207. PubMed ID: 15875080
[TBL] [Abstract][Full Text] [Related]
15. A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer.
Takada M; Kataoka A; Toi M; Bando H; Toyama K; Horiguchi S; Ueno T; Linder S; Saji S; Hayashi Y; Funata N; Kinoshita J; Murakami S; Ohono S
Int J Oncol; 2004 Aug; 25(2):397-405. PubMed ID: 15254737
[TBL] [Abstract][Full Text] [Related]
16. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy.
Vincent-Salomon A; Rousseau A; Jouve M; Beuzeboc P; Sigal-Zafrani B; Fréneaux P; Rosty C; Nos C; Campana F; Klijanienko J; Al Ghuzlan A; Sastre-Garau X;
Eur J Cancer; 2004 Jul; 40(10):1502-8. PubMed ID: 15196533
[TBL] [Abstract][Full Text] [Related]
17. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy.
Tacca O; Penault-Llorca F; Abrial C; Mouret-Reynier MA; Raoelfils I; Durando X; Achard JL; Gimbergues P; Curé H; Chollet P
Oncologist; 2007 Jun; 12(6):636-43. PubMed ID: 17602055
[TBL] [Abstract][Full Text] [Related]
18. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems.
Genestie C; Zafrani B; Asselain B; Fourquet A; Rozan S; Validire P; Vincent-Salomon A; Sastre-Garau X
Anticancer Res; 1998; 18(1B):571-6. PubMed ID: 9568179
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer.
Chakravarthy AB; Kelley MC; McLaren B; Truica CI; Billheimer D; Mayer IA; Grau AM; Johnson DH; Simpson JF; Beauchamp RD; Jones C; Pietenpol JA
Clin Cancer Res; 2006 Mar; 12(5):1570-6. PubMed ID: 16533783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
